Do analysts rate ONCY or PRTC?

Oncolytics Biotech currently has a consensus target price of $5.00, indicating a potential upside of 483.77%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ONCY or PRTC?

Oncolytics Biotech has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is ONCY or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% PureTech Health N/A N/A N/A

Does the media prefer ONCY or FHTX?

In the previous week, Oncolytics Biotech had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.34 beat Oncolytics Biotech's score of -0.04 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XFOR or ONCY?

In the previous week, Oncolytics Biotech had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for Oncolytics Biotech and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat Oncolytics Biotech's score of -0.04 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, LXEO or ONCY?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is LXEO or ONCY more profitable?

Lexeo Therapeutics' return on equity of -41.85% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media refer more to LXEO or ONCY?

In the previous week, Lexeo Therapeutics had 4 more articles in the media than Oncolytics Biotech. MarketBeat recorded 7 mentions for Lexeo Therapeutics and 3 mentions for Oncolytics Biotech. Lexeo Therapeutics' average media sentiment score of 1.49 beat Oncolytics Biotech's score of -0.04 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ONCY or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is ONCY or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to ONCY or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 3 mentions for Oncolytics Biotech. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Oncolytics Biotech's score of -0.04 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncolytics Biotech (ONCY) Competitors

$0.86 -0.02 (-2.67%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.85 0.00 (-0.29%)

As of 04:00 AM Eastern

Compare

ONCY vs. PRTC, FHTX, XFOR, LXEO, and RCKT

Should you buy Oncolytics Biotech stock or one of its competitors? Oncolytics Biotech's main competitors and comparable companies include PureTech Health (PRTC), Foghorn Therapeutics (FHTX), X4 Pharmaceuticals (XFOR), Lexeo Therapeutics (LXEO), and Rocket Pharmaceuticals (RCKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncolytics Biotech compare to PureTech Health?

Oncolytics Biotech (NASDAQ:ONCY) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Oncolytics Biotech has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Oncolytics Biotech had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.04 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Neutral
PureTech Health	Neutral

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncolytics Biotech currently has a consensus target price of $5.00, indicating a potential upside of 483.77%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Oncolytics Biotech has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

PureTech Health's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
PureTech Health	N/A	N/A	N/A

Summary

Oncolytics Biotech beats PureTech Health on 7 of the 12 factors compared between the two stocks.

How does Oncolytics Biotech compare to Foghorn Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oncolytics Biotech had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.34 beat Oncolytics Biotech's score of -0.04 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Foghorn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncolytics Biotech has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

Oncolytics Biotech has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Foghorn Therapeutics	$30.91M	9.36	-$74.28M	-$0.98	N/A

Oncolytics Biotech currently has a consensus price target of $5.00, suggesting a potential upside of 483.77%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 134.67%. Given Oncolytics Biotech's higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Oncolytics Biotech has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Summary

Foghorn Therapeutics beats Oncolytics Biotech on 9 of the 15 factors compared between the two stocks.

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

X4 Pharmaceuticals currently has a consensus price target of $11.25, indicating a potential upside of 178.47%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 483.77%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Oncolytics Biotech had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for Oncolytics Biotech and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat Oncolytics Biotech's score of -0.04 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oncolytics Biotech has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

X4 Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Oncolytics Biotech has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

Summary

Oncolytics Biotech beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Lexeo Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 287.40%. Oncolytics Biotech has a consensus target price of $5.00, suggesting a potential upside of 483.77%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lexeo Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Lexeo Therapeutics' return on equity of -41.85% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Lexeo Therapeutics had 4 more articles in the media than Oncolytics Biotech. MarketBeat recorded 7 mentions for Lexeo Therapeutics and 3 mentions for Oncolytics Biotech. Lexeo Therapeutics' average media sentiment score of 1.49 beat Oncolytics Biotech's score of -0.04 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

Summary

Lexeo Therapeutics beats Oncolytics Biotech on 10 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Oncolytics Biotech (NASDAQ:ONCY) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Oncolytics Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 483.77%. Rocket Pharmaceuticals has a consensus price target of $8.57, suggesting a potential upside of 126.16%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Oncolytics Biotech has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Rocket Pharmaceuticals' return on equity of -52.77% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 3 mentions for Oncolytics Biotech. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Oncolytics Biotech's score of -0.04 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rocket Pharmaceuticals beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.21M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.52	12.66	273.29	25.25
Price / Sales	N/A	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-17.13	16.39	12.92	6.14
Net Income	-$28.76M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-0.01%	0.36%	0.60%	-0.27%
1 Month Performance	5.68%	8.53%	5.72%	0.68%
1 Year Performance	-20.69%	52.66%	25.33%	14.84%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	1.5856 of 5 stars	$0.86 -2.7%	$5.00 +483.8%	-26.2%	$112.21M	N/A	N/A	30	Analyst Revision
PRTC PureTech Health	0.0041 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
FHTX Foghorn Therapeutics	1.9449 of 5 stars	$6.87 -2.8%	$11.43 +66.4%	-7.6%	$419.85M	$30.91M	N/A	120
XFOR X4 Pharmaceuticals	1.9832 of 5 stars	$4.05 +0.2%	$11.25 +177.8%	+29.5%	$400.55M	$35.11M	N/A	80
LXEO Lexeo Therapeutics	2.6419 of 5 stars	$4.92 +0.8%	$18.75 +281.1%	-1.6%	$400.39M	N/A	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. PRTC, FHTX, XFOR, LXEO, and RCKT

How does Oncolytics Biotech compare to PureTech Health?

Summary

How does Oncolytics Biotech compare to Foghorn Therapeutics?

Summary

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

Summary

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Summary

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. PRTC, FHTX, XFOR, LXEO, and RCKT

How does Oncolytics Biotech compare to PureTech Health?

Which has higher earnings & valuation, ONCY or PRTC?

Does the media prefer ONCY or PRTC?

Do insiders & institutionals believe in ONCY or PRTC?

Do analysts rate ONCY or PRTC?

Which has more risk & volatility, ONCY or PRTC?

Is ONCY or PRTC more profitable?

Summary

How does Oncolytics Biotech compare to Foghorn Therapeutics?

Do institutionals and insiders have more ownership in ONCY or FHTX?

Does the media prefer ONCY or FHTX?

Which has more risk & volatility, ONCY or FHTX?

Which has preferable valuation and earnings, ONCY or FHTX?

Do analysts recommend ONCY or FHTX?

Is ONCY or FHTX more profitable?

Summary

How does Oncolytics Biotech compare to X4 Pharmaceuticals?

Do analysts prefer XFOR or ONCY?

Does the media prefer XFOR or ONCY?

Do institutionals and insiders believe in XFOR or ONCY?

Which has better earnings & valuation, XFOR or ONCY?

Which has more volatility and risk, XFOR or ONCY?

Is XFOR or ONCY more profitable?

Summary

How does Oncolytics Biotech compare to Lexeo Therapeutics?

Do analysts recommend LXEO or ONCY?

Which has more risk & volatility, LXEO or ONCY?

Is LXEO or ONCY more profitable?

Do insiders & institutionals hold more shares of LXEO or ONCY?

Does the media refer more to LXEO or ONCY?

Which has better valuation and earnings, LXEO or ONCY?

Summary

How does Oncolytics Biotech compare to Rocket Pharmaceuticals?

Do analysts rate ONCY or RCKT?

Which has more volatility & risk, ONCY or RCKT?

Which has higher valuation and earnings, ONCY or RCKT?

Is ONCY or RCKT more profitable?

Do insiders & institutionals hold more shares of ONCY or RCKT?

Does the media refer more to ONCY or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools